摘要
目的:探讨在中国男性人群中吸烟、烟碱型乙酰胆碱受体亚单位β2(CHRNB2)上rs2072659与rs2072660位点多态性与肺癌的关联。方法:采用病例对照研究设计,收集204例男性原发性肺癌患者和821例正常健康男性作为研究对象。采用结构式问卷调查人口学特征、吸烟行为及健康相关行为等信息,检测静脉血CHRNB2基因簇上单核苷酸的多态性位点rs2072659与rs2072660的多态性。应用KruskalWallis检验方法和多因素Logistic回归模型分析吸烟、CHRNB2基因簇上的基因多态性与肺癌的关联。结果:运用多因素logistic回归校正年龄、职业、教育程度、婚姻等混杂因素后,CHRNB2rs2072660 C/T基因型较C/C基因型相比,发生吸烟的风险降低(OR=0.710,95%CI=0.530-0.953);但相对于C/C基因型而言,CHRNB2rs2072660 C/T(OR=1.71,95%CI=1.17-2.50)发生肺癌的风险增加,rs2072659与rs207260的多态性和吸烟对肺癌不存在交互作用。结论:吸烟和CHRNB2中的rs207260的多态性是肺癌发生的危险因素。
Objective: To investigate the correlation of smoking and nicotinic acetylcholine receptor beta2 subunit gene( CHRNB2) gene polymorphisms at rs2072659/rs2072660 loci with lung cancer in Chinese males.Methods: A case-control study was employed with a total of 204 male lung cancer patients and 821 healthy control subjects enrolled in the study. A structured questionnaire was used to investigate the demographic characteristics,smoking behaviors and health-related behaviors. The CHRNB2 single nucleotide gene polymorphisms at rs2072659 and rs2072660 loci in the venous blood were measured. Kruskal-Wallis test and multivariate logistic regression model were used to determine the correlation of smoking and CHRNB2 gene polymorphisms with lung cancer. Results: After adjusting for confounding factors such as age,occupation,education level,and marriage status by using multivariate logistic regression,CHRNB 2 rs2072660 C/T genotype showed a lower risk of smoking than C/C genotype( OR = 0. 710,95% CI = 0. 530-0. 953). However,compared with C/C genotype,CHRNB2 rs2072660 C/T genotype showed an increased risk of developing lung cancer( OR =1.71,95% CI = 1. 17-2. 50). There was no interaction between rs2072659 and rs207260 polymorphisms and smoking on lung cancer. Conclusion: Smoking and CHRNB2 polymorphism at rs207260 are risk factors for the occurrence of lung cancer.
作者
张亚雷
蔡霞
庞玲娟
江梅
Zhang Yalei;Cai Xia;Pang Lingjuan;Jiang Mei(Department of Thoracic Surgery,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510120,China;Guangzhou Food and Drug Administration,Guangzhou,Guangdong 510160,China;Medical Affair Department,Pfizer Investment Co.,Ltd.,Beijing 100010,China;the First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong 510120,China)
出处
《广州医科大学学报》
2018年第2期1-5,33,共6页
Academic Journal of Guangzhou Medical University
基金
广东省科技计划(2011B061300111)